Researchers' work from Seoul National University focuses on smallpox vaccines
2007 NOV 12 -- According to recent research from Seoul, South Korea, "The aim of the present study was to investigate the kinetics of Immoral and cell-mediated immune responses to a new cell culture-derived smallpox vaccine (CJ-50300, CJ Corporation, South Korea) in 18 vaccinia-naive volunteers." "All subjects achieved positive Immoral immune responses (plaque reduction neutralizing antibody assay) 28 days after vaccination, and cell-mediated immune responses (ELISPOT assay) 14 days after vaccination. Humoral immune responses increased up to 28 days after vaccination and were maintained up to 56 days after vaccination," wrote S.H. Kim and colleagues, Seoul National University. The researchers concluded: "In contrast, cell-mediated immune responses increased up to 14 days after vaccination and steadily decreased to 56 days after vaccination [Clinical Trial No. NCT 00336635]." Kim and colleagues published their study in Vaccine (Detailed kinetics of immune responses to a new cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine, 2007;25(33):6287-6291). For additional information, contact M.D. Oh, Seoul National University, Dept. of Internal Medical, Seoul 110744, South Korea. Publisher contact information for the journal Vaccine is: Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. Keywords: South Korea, Seoul, Immunization, Smallpox Vaccines, Vaccination, Seoul National University. This article was prepared by Pharma Business Week editors from staff and other reports. Copyright 2007, Pharma Business Week via NewsRx.com.
|